Eligibility

Ages Eligible for Study

18 years to 70 years

Genders Eligible for Study

Both

Keywords

Nasopharyngeal Carcinoma, Chemoradiotherapy, and Accelerated Fractionation

Sponsors

Other

hong Kong Cancer Fund

Other

The Hong Kong Anti-Cancer Society

Other

Hong Kong Nasopharyngeal Cancer Study Group Limited

Inclusion Criteria

- histologically proven nasopharyngeal carcinoma for primary treatment with radical
intent

- non-keratinizing or undifferentiated type

- stage III-IVB (by AJCC/UICC 6th edition)

- ECOG Performance status less or equal to 2

- Marrow: WBC >= 4 and platelet >=100

- Renal: creatinine clearance >=60

- Informed consent

Exclusion Criteria

- Primary treatment with palliative intent

- WHO type I squamous cell carcinoma or adenocarcinoma

- Evidence of distant metastases

- Patient is pregnant or lactating

- Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
in-situ cervical cancer or other cancer for which the patient has been disease-free
for 5 years

Detailed Description

The objectives of this clinical study are threefold: 1. To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant chemotherapy to radiation. 2. To test whether replacing fluorouracil with Xeloda in combining with cisplatin in the chemotherapy plan will maintain or improve further the chemotherapy benefits while reducing the duration of hospital stay. 3. To see if accelerated fractionation radiotherapy can improve the outcome of patients as compared with conventional fractionation radiotherapy.